Cancer Research AACR Conference on Molecular Diagnostics - 2008 Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nimmanapalli, R.
Right arrow Articles by Bhalla, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nimmanapalli, R.
Right arrow Articles by Bhalla, K.
[Cancer Research 61, 1799-1804, March 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Geldanamycin and Its Analogue 17-Allylamino-17-demethoxygeldanamycin Lowers Bcr-Abl Levels and Induces Apoptosis and Differentiation of Bcr-Abl-positive Human Leukemic Blasts

Ramadevi Nimmanapalli, Erica O’Bryan and Kapil Bhalla1

Interdisciplinary Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa, Florida 33612

HL-60/Bcr-Abl cells, with ectopic expression of p185 Bcr-Abl tyrosine kinase (TK), and K562 cells, with endogenous expression of p210 Bcr-Abl TK, display a high degree of resistance against antileukemic drug-induced apoptosis (G. Fang et al., Blood, 96: 2246–2256, 2000). Present studies demonstrate that treatment with ansamycin antibiotic geldanamycin (GA), or its less toxic analogue 17-allylamino-17-demethoxygeldanamycin (17-AAG), induces cytosolic accumulation of cytochrome c and cleavage and activities of caspase-9 and caspase-3, triggering apoptosis of HL-60/Bcr-Abl and K562 cells. GA or 17-AAG down-regulated intracellular Bcr-Abl and c-Raf protein levels, as well as reduced Akt kinase activity. Similar to Raf-1, v-Src, and Her-2-neu, Bcr-Abl TK has chaperone association with heat shock protein 90 (Hsp90). By binding and inhibiting Hsp90, GA or 17-AAG treatment shifted the binding of Bcr-Abl from Hsp90 to Hsp70 and induced the proteasomal degradation of Bcr-Abl, because cotreatment with proteasome inhibitor PSC341 reduced both GA (or 17-AAG)-mediated down-regulation of Bcr-Abl levels and inhibited apoptosis of HL-60/Bcr-Abl and K562 cells. These data establish the in vitro activity of GA and 17-AAG against Bcr-Abl-positive leukemic cells and support the in vivo investigation of 17-AAG against Bcr-Abl-positive leukemias.




This article has been cited by other articles:


Home page
 BloodHome page
R. Rao, W. Fiskus, Y. Yang, P. Lee, R. Joshi, P. Fernandez, A. Mandawat, P. Atadja, J. E. Bradner, and K. Bhalla
HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
Blood, September 1, 2008; 112(5): 1886 - 1893.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Peng, J. Brain, Y. Hu, A. Goodrich, L. Kong, D. Grayzel, R. Pak, M. Read, and S. Li
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells
Blood, July 15, 2007; 110(2): 678 - 685.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. A. Bartholomeusz, M. Talpaz, V. Kapuria, L. Y. Kong, S. Wang, Z. Estrov, W. Priebe, J. Wu, and N. J. Donato
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells
Blood, April 15, 2007; 109(8): 3470 - 3478.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Xu and L. Neckers
Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells
Clin. Cancer Res., March 15, 2007; 13(6): 1625 - 1629.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bagatell, L. Gore, M. J. Egorin, R. Ho, G. Heller, N. Boucher, E. G. Zuhowski, J. A. Whitlock, S. P. Hunger, A. Narendran, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study
Clin. Cancer Res., March 15, 2007; 13(6): 1783 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Mitchell, M. A. Park, G. Zhang, S. I. Han, H. Harada, R. A. Franklin, A. Yacoub, P.-L. Li, P. B. Hylemon, S. Grant, et al.
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
Mol. Cancer Ther., February 1, 2007; 6(2): 618 - 632.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Chen, W.-M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, and C.-K. Qu
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl
Blood, January 15, 2007; 109(2): 778 - 785.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Matei, M. Satpathy, L. Cao, Y.-C. Lai, H. Nakshatri, and D. B. Donner
The Platelet-derived Growth Factor Receptor {alpha} Is Destabilized by Geldanamycins in Cancer Cells
J. Biol. Chem., January 5, 2007; 282(1): 445 - 453.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
E. Schmitt, M. Gehrmann, M. Brunet, G. Multhoff, and C. Garrido
Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy
J. Leukoc. Biol., January 1, 2007; 81(1): 15 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Chen, V. Gandhi, and W. Plunkett
A Sequential Blockade Strategy for the Design of Combination Therapies to Overcome Oncogene Addiction in Chronic Myelogenous Leukemia.
Cancer Res., November 15, 2006; 66(22): 10959 - 10966.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. I. Robles, M. H. Wright, B. Gandhi, S. S. Feis, C. L. Hanigan, A. Wiestner, and L. Varticovski
Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines.
Clin. Cancer Res., November 1, 2006; 12(21): 6547 - 6556.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al.
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Blood, July 15, 2006; 108(2): 645 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. K. Nguyen, M. Rahmani, N. Gao, L. Kramer, A. S. Corbin, B. J. Druker, P. Dent, and S. Grant
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2239 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. Sohn, G. Totzke, F. Essmann, K. Schulze-Osthoff, B. Levkau, and R. U. Janicke
The proteasome is required for rapid initiation of death receptor-induced apoptosis.
Mol. Cell. Biol., March 1, 2006; 26(5): 1967 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Banerji, M. Walton, F. Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson, and P. Workman
Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models
Clin. Cancer Res., October 1, 2005; 11(19): 7023 - 7032.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cortes and H. Kantarjian
New Targeted Approaches in Chronic Myeloid Leukemia
J. Clin. Oncol., September 10, 2005; 23(26): 6316 - 6324.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al.
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS
J. Biol. Chem., July 22, 2005; 280(29): 26729 - 26734.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood, July 1, 2005; 106(1): 318 - 327.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Banerji, A. O'Donnell, M. Scurr, S. Pacey, S. Stapleton, Y. Asad, L. Simmons, A. Maloney, F. Raynaud, M. Campbell, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
J. Clin. Oncol., June 20, 2005; 23(18): 4152 - 4161.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
R. Chen and W. Plunkett
Sequential Blockade of Oncogenic Kinases
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 344 - 348.
[Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Rahmani, E. Reese, Y. Dai, C. Bauer, L. B. Kramer, M. Huang, R. Jove, P. Dent, and S. Grant
Cotreatment with Suberanoylanilide Hydroxamic Acid and 17-Allylamino 17-demethoxygeldanamycin Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI571 (Imatinib Mesylate) in Association with Down-Regulation of Bcr-Abl, Abrogation of Signal Transducer and Activator of Transcription 5 Activity, and Bax Conformational Change
Mol. Pharmacol., April 1, 2005; 67(4): 1166 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. Grem, G. Morrison, X.-D. Guo, E. Agnew, C. H. Takimoto, R. Thomas, E. Szabo, L. Grochow, F. Grollman, J. M. Hamilton, et al.
Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors
J. Clin. Oncol., March 20, 2005; 23(9): 1885 - 1893.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Petersen Shay, Z. Wang, P.-x. Xing, I. F.C. McKenzie, and N. S. Magnuson
Pim-1 Kinase Stability Is Regulated by Heat Shock Proteins and the Ubiquitin-Proteasome Pathway
Mol. Cancer Res., March 1, 2005; 3(3): 170 - 181.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. George, P. Bali, S. Annavarapu, A. Scuto, W. Fiskus, F. Guo, C. Sigua, G. Sondarva, L. Moscinski, P. Atadja, et al.
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
Blood, February 15, 2005; 105(4): 1768 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Bali, P. George, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, A. Scuto, S. Annavarapu, W. Fiskus, et al.
Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Clin. Cancer Res., August 1, 2004; 10(15): 4991 - 4997.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. George, P. Bali, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, W. Fiskus, A. Scuto, S. Annavarapu, et al.
Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Cancer Res., May 15, 2004; 64(10): 3645 - 3652.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. T. Jones, E. Addison, J. M. North, M. W. Lowdell, A. V. Hoffbrand, A. B. Mehta, K. Ganeshaguru, N. I. Folarin, and R. G. Wickremasinghe
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs
Blood, March 1, 2004; 103(5): 1855 - 1861.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. J. H. Arlander, A. K. Eapen, B. T. Vroman, R. J. McDonald, D. O. Toft, and L. M. Karnitz
Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
J. Biol. Chem., December 26, 2003; 278(52): 52572 - 52577.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Rahmani, C. Yu, Y. Dai, E. Reese, W. Ahmed, P. Dent, and S. Grant
Coadministration of the Heat Shock Protein 90 Antagonist 17-Allylamino- 17-demethoxygeldanamycin with Suberoylanilide Hydroxamic Acid or Sodium Butyrate Synergistically Induces Apoptosis in Human Leukemia Cells
Cancer Res., December 1, 2003; 63(23): 8420 - 8427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nimmanapalli, P. Bali, E. O'Bryan, L. Fuino, F. Guo, J. Wu, P. Houghton, and K. Bhalla
Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells
Cancer Res., November 15, 2003; 63(22): 7950 - 7958.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. von Bubnoff, D. R. Veach, W. T. Miller, W. Li, J. Sanger, C. Peschel, W. G. Bornmann, B. Clarkson, and J. Duyster
Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine-Type Small Molecule Kinase Inhibitors
Cancer Res., October 1, 2003; 63(19): 6395 - 6404.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, H.-G. Wang, P. Atadja, and K. Bhalla
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
Mol. Cancer Ther., October 1, 2003; 2(10): 971 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski, C. Smith, J. Wu, R. Jove, et al.
Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells
Cancer Res., August 15, 2003; 63(16): 5126 - 5135.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. P. Goetz, D. O. Toft, M. M. Ames, and C. Erlichman
The Hsp90 chaperone complex as a novel target for cancer therapy
Ann. Onc., August 1, 2003; 14(8): 1169 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Nimmanapalli, E. O'Bryan, D. Kuhn, H. Yamaguchi, H.-G. Wang, and K. N. Bhalla
Regulation of 17-AAG--induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG--mediated down-regulation of Akt, Raf-1, and Src kinases
Blood, July 1, 2003; 102(1): 269 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Yu, M. Rahmani, J. Almenara, M. Subler, G. Krystal, D. Conrad, L. Varticovski, P. Dent, and S. Grant
Histone Deacetylase Inhibitors Promote STI571-mediated Apoptosis in STI571-sensitive and -resistant Bcr/Abl+ Human Myeloid Leukemia Cells
Cancer Res., May 1, 2003; 63(9): 2118 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Villa, M. Folini, C. D. Porta, A. Valentini, M. Pennati, M. G. Daidone, and N. Zaffaroni
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells
Carcinogenesis, May 1, 2003; 24(5): 851 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Sausville
Is Another Bcr-Abl Inhibitor Needed for Chronic Myelogenous Leukemia?
Clin. Cancer Res., April 1, 2003; 9(4): 1233 - 1234.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Tikhomirov and G. Carpenter
Identification of ErbB-2 Kinase Domain Motifs Required for Geldanamycin-induced Degradation
Cancer Res., January 1, 2003; 63(1): 39 - 43.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Wittmann, P. Bali, S. Donapaty, R. Nimmanapalli, F. Guo, H. Yamaguchi, M. Huang, R. Jove, H. G. Wang, and K. Bhalla
Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis
Cancer Res., January 1, 2003; 63(1): 93 - 99.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. V. Melo, T. P. Hughes, and J. F. Apperley
Chronic Myeloid Leukemia
Hematology, January 1, 2003; 2003(1): 132 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. La Rosee, A. S. Corbin, E. P. Stoffregen, M. W. Deininger, and B. J. Druker
Activity of the Bcr-Abl Kinase Inhibitor PD180970 against Clinically Relevant Bcr-Abl Isoforms That Cause Resistance to Imatinib Mesylate (Gleevec, STI571)
Cancer Res., December 15, 2002; 62(24): 7149 - 7153.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nimmanapalli, E. O'Bryan, M. Huang, P. Bali, P. K. Burnette, T. Loughran, J. Tepperberg, R. Jove, and K. Bhalla
Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD180970 and 17-Allylamino-17-demethoxygeldanamycin
Cancer Res., October 15, 2002; 62(20): 5761 - 5769.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. E. Gorre, K. Ellwood-Yen, G. Chiosis, N. Rosen, and C. L. Sawyers
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
Blood, September 26, 2002; 100(8): 3041 - 3044.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Yu, G. Krystal, P. Dent, and S. Grant
Flavopiridol Potentiates STI571-induced Mitochondrial Damage and Apoptosis in BCR-ABL-positive Human Leukemia Cells
Clin. Cancer Res., September 1, 2002; 8(9): 2976 - 2984.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. S. Isaacs, Y.-J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttitta, and L. M. Neckers
Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha -degradative Pathway
J. Biol. Chem., August 9, 2002; 277(33): 29936 - 29944.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
V. Poulaki, C. S. Mitsiades, V. Kotoula, S. Tseleni-Balafouta, A. Ashkenazi, D. A. Koutras, and N. Mitsiades
Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells
Am. J. Pathol., August 1, 2002; 161(2): 643 - 654.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Fujita, S. Sato, A. Ishida, and T. Tsuruo
Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1
J. Biol. Chem., March 15, 2002; 277(12): 10346 - 10353.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Bonvini, T. Gastaldi, B. Falini, and A. Rosolen
Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-Client Tyrosine Kinase: Down-Regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK+ CD30+ Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino,17-demethoxygeldanamycin
Cancer Res., March 1, 2002; 62(5): 1559 - 1566.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Yu, G. Krystal, L. Varticovksi, R. McKinstry, M. Rahmani, P. Dent, and S. Grant
Pharmacologic Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase/Mitogen-activated Protein Kinase Inhibitors Interact Synergistically with STI571 to Induce Apoptosis in Bcr/Abl-expressing Human Leukemia Cells
Cancer Res., January 1, 2002; 62(1): 188 - 199.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Turturro, M. D. Arnold, A. Y. Frist, and K. Pulford
Model of Inhibition of the NPM-ALK Kinase Activity by Herbimycin A
Clin. Cancer Res., January 1, 2002; 8(1): 240 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Sausville
Combining Cytotoxics and 17-Allylamino, 17-Demethoxygeldanamycin: Sequence and Tumor Biology Matters : Commentary re: P. Munster et al., Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB- and Schedule-dependent Manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Clin. Cancer Res., August 1, 2001; 7(8): 2155 - 2158.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Tikhomirov and G. Carpenter
Caspase-dependent Cleavage of ErbB-2 by Geldanamycin and Staurosporin
J. Biol. Chem., August 31, 2001; 276(36): 33675 - 33680.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.